Skip to Main Content

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Conditions

Diseases of the Digestive System - Liver

Phase III

What is the purpose of this trial?

Brief Summary:

A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)

  • Trial with
    CymaBay Therapeutics, Inc.
  • Start Date
    12/12/2018
  • End Date
    12/30/2020
Trial Image

For more information about this study, contact:

Laura Cusack

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    12/21/2018
  • Study HIC
    #2000024082